Takeda Pharmaceutical (TAK) EBT Margin Growth (3y) (2020 - 2026)

Takeda Pharmaceutical (TAK) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 1,840.00
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn -134.00
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -5,626.00
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn -1,686.00
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn -1,570.00
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 5,487.00
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn -225.00
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 3,138.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -5,626.00
Dec 31, 2025 -5,134.00
Sep 30, 2025 242.00
Jun 30, 2025 -583.00
Mar 31, 2025 -1,046.00
Dec 31, 2024 -1,820.00
Sep 30, 2024 73.00
Jun 30, 2024 -1,217.00
Mar 31, 2024 -568.00
Dec 31, 2023 -856.00
Sep 30, 2023 1,078.00
Jun 30, 2023 -349.00
Mar 31, 2023 -1,514.00
Sep 30, 2022 384.00
Jun 30, 2022 1,480.00
Dec 31, 2021 -152.00
Jun 30, 2021 262.00
Mar 31, 2021 3,462.00
Dec 31, 2020 187.00